Ibba, L.; Falcidia, C.; Di Giulio, S.; Bianco, M.; Valenti, M.; Facheris, P.; Narcisi, A.; Costanzo, A.; Gargiulo, L.
Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study. J. Clin. Med. 2025, 14, 2953.
https://doi.org/10.3390/jcm14092953
AMA Style
Ibba L, Falcidia C, Di Giulio S, Bianco M, Valenti M, Facheris P, Narcisi A, Costanzo A, Gargiulo L.
Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study. Journal of Clinical Medicine. 2025; 14(9):2953.
https://doi.org/10.3390/jcm14092953
Chicago/Turabian Style
Ibba, Luciano, Costanza Falcidia, Sara Di Giulio, Matteo Bianco, Mario Valenti, Paola Facheris, Alessandra Narcisi, Antonio Costanzo, and Luigi Gargiulo.
2025. "Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study" Journal of Clinical Medicine 14, no. 9: 2953.
https://doi.org/10.3390/jcm14092953
APA Style
Ibba, L., Falcidia, C., Di Giulio, S., Bianco, M., Valenti, M., Facheris, P., Narcisi, A., Costanzo, A., & Gargiulo, L.
(2025). Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study. Journal of Clinical Medicine, 14(9), 2953.
https://doi.org/10.3390/jcm14092953
